<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640846</url>
  </required_header>
  <id_info>
    <org_study_id>K050711</org_study_id>
    <nct_id>NCT02640846</nct_id>
  </id_info>
  <brief_title>Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock</brief_title>
  <acronym>SCLM</acronym>
  <official_title>Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects milrinon and levosimandan on n heart
      function in septic cardiomyopathy and how norepinephrine affects the left and right
      ventricular function in patients with septick shock using pulmonary artery catheter,
      conventional and strain echocardiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study where 30 patients with septic chock during the care in ICU, will
      be included. Patients with a history of previous heart disease are excluded from the study.
      Each patient is in need of norepinephrine infusion and on mechanical ventilation. Initially
      the mean arterial pressure (MAP) is randomly changed from 60 to 75 and then to 90 mmHg.
      Hemodynamic variables as blood pressure, cardiac output, pulmonary artery occlusion pressure
      (PAOP) will be registerd at each MAP-level, arterial line and pulmonary artery catheter (PAC)
      and the cardiac function will be assessed with conventional and strain echocardiography.
      Then, if the echocardiogram shows impaired LV-function will the patient be randomized to
      receive either Milrinone or Levosimendan. Hemodynamic variables as blood pressure, cardiac
      output, pulmonary artery occlusion pressure (PAOP) will be registered again, as well the
      cardiac function with conventional and strain echocardiography. Echocardiograms will be
      analysed for the determination of LV an RV strain. Potential differences between different
      levels of blood pressure as well as effects of Milrinone or Levosimendan on hemodynamic and
      echocardiographyc variables will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in LV systolic strain</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Changes in LV systolic function (global strain) will be assessed by 2D speckle tracking echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in RV systolic strain</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Changes in RV systolic function (RV free wall strain) will be assessed by 2D speckle tracking echocardiography</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Septic Shock</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.</description>
    <arm_group_label>Norepinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.</description>
    <arm_group_label>Milrinone</arm_group_label>
    <other_name>Corotrope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock.

          -  All patients will be resuscitated with fluids before the inclusion.

          -  Need of Norepinephrine infusion.

          -  Myocardial dysfunction in echocardiogram, either LVEF &lt; 50% or Global Left Ventricular
             Systolic strain over -15%.

        Exclusion Criteria:

          -  History of previous heart disease or pulmonary hypertension.

          -  Age &lt; 18 years.

          -  Cardiac arrhythmia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska Academy, dep of clinical science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central intensivvårdsavdelning Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Keti Dalla</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Levosimendan</keyword>
  <keyword>Milrinone</keyword>
  <keyword>Myocardial strain</keyword>
  <keyword>Septic cardiomyopathy</keyword>
  <keyword>Norepinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Milrinone</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

